# EDGAR Filing Document

**Accession Number:** 0001450416
**File Stem:** 0001104659-23-012214
**Filing Date:** 2023-2
**Character Count:** 13107
**Document Hash:** 0da7007b56f881cf6ab462522ae39efe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-012214.hdr.sgml**: 20230208

**ACCESSION NUMBER**: 0001104659-23-012214

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20230208

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230208

**DATE AS OF CHANGE**: 20230208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LexaGene Holdings Inc.
- **CENTRAL INDEX KEY:** 0001450416
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0228

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56456
- **FILM NUMBER:** 23597328

**BUSINESS ADDRESS:**
- **STREET 1:** 500 CUMMINGS CTR., SUITE 4550
- **CITY:** BEVERLY
- **STATE:** MA
- **ZIP:** 01915
- **BUSINESS PHONE:** 800-215-1824

**MAIL ADDRESS:**
- **STREET 1:** 500 CUMMINGS CTR., SUITE 4550
- **CITY:** BEVERLY
- **STATE:** MA
- **ZIP:** 01915

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STONESHIELD CAPITAL CORP.
- **DATE OF NAME CHANGE:** 20100729

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** STONESHIELD CAPITAL CORP
- **DATE OF NAME CHANGE:** 20081119

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM 8-K**

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** February 8, 2023

![](tm235853d1_8kimg01.jpg)

**LEXAGENE HOLDINGS INC.**

(Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **British Columbia** | **000-56456** | **None** |
| (State or other jurisdiction of<br> incorporation or organization) | ***Commission File Number:*** | (I.R.S. Employer Identification No.) |
| **500 Cummings Center, Suite 4550,**<br> **Beverly Massachusetts** |  | **01915** |
| *(Address of principal executive offices)* |  | (Zip Code) |

---

**(800) 215-1824**

(Registrant's telephone number, including area code)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| N/A | **N/A** | N/A |

---

**SECTION 7.01 – REGULATION FD**

**Item 7.01 Regulation FD Disclosure**

On February 8, 2023, the Company issued a news release providing an update on the Company's efforts to have the MiQLab System adopted for routine testing during the manufacturing of biologics. A copy of the news release is furnished as Exhibit 99.1 hereto.

**SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS**

**Item 9.01 Exhibits.**

(d) Exhibits

104 Cover Page Interactive Data File (embedded within the Inline XBRL Document) <br> [99.1](tm235853d1_ex99-1.htm) [Press Release dated February 8, 2023](tm235853d1_ex99-1.htm)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **LEXAGENE HOLDINGS INC.** | **LEXAGENE HOLDINGS INC.** |
| Date: February 8, 2023 | By: | /s/ Jeffrey Mitchell |
|  |  | Name: Jeffrey Mitchell |
|  |  | Title: Chief Financial Officer |

---

**Exhibit Index**

[99.1](tm235853d1_ex99-1.htm) [Press Release, dated February 8, 2023](tm235853d1_ex99-1.htm) <br> 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

## Exhibit 99.1

**Exhibit 99.1**

![](tm235853d1_ex99-1img002.jpg)

**LexaGene Provides Update on BioPharma Sector**

BEVERLY, Mass. USA – Feb 8, 2023 – <u>LexaGene Holdings, Inc.</u>, <u>(</u><u>OTCQB: LXXGF; TSX-V: LXG)</u> ("LexaGene" or the "Company"), an innovative, molecular diagnostics company that has commercialized the <u>MiQLab<sup>TM</sup> System</u> for automated, genetic testing, is pleased to provide the following update on the Company's efforts to have the MiQLab System adopted for routine testing during the manufacturing of biologics.

Dr. Jack Regan, CEO and Founder of LexaGene commented, "We continue to work with both of our biopharma customers - a more traditional biopharma company with a market cap that is >$100B and a leading Contract Drug Manufacturing Organization (CDMO) with a market cap that is >$40B. Individuals in both organizations have indicated that our technology has the potential to benefit their respective companies and that our technology can be of great value to the entire industry."

He continued, "We have sold our technology into the R&D groups of both companies. Although this is a critical first step, our goal is to get into manufacturing where regular testing at an average-sized plant could generate ~ $5M in revenue per year, and the entire annual testing market opportunity is estimated to be $10B in size.<sup>1</sup>

For our traditional biopharma customer, the execution of the feasibility studies was a great start and they have set aside time in April to start to a formal campaign within their facility that will focus on using the MiQLab System in the optimization of different manufacturing unit operations. These studies will include testing for *Mycoplasma*.

Per request from this customer, we have designed highly sensitive, RNA-based assays for bacteria (including *Escherichia coli*) and Minute Virus of Mice (MVM), and we are about to start designing an assay for Vesivirus 2117, as these contaminants are of highest interest for them.

During our conversations with our traditional biopharma customer, they suggested presenting at <u>the 2023 National Institute for Innovation in Manufacturing Biopharmaceuticals ("NIIMBL") National Meeting</u> being held in June in Washington, DC. NIIMBL is a public-private partnership whose mission is to accelerate biopharmaceutical innovation and advance other industry objectives.

Our CDMO customer is in the process of submitting the data they've generated using a MiQLab System for a presentation at the <u>15th Annual Bioprocessing Summit</u>, which is to be held in August in Boston, MA. The title of their talk is "Risk Reduction by Rapid Automated Detection of Common Biomanufacturing Contaminants."

Dr. Regan concluded, "Having our biopharma customers request to present the data they generated using our technology at a conference is a fantastic endorsement and there is no better advertising. This exposure will help LexaGene achieve better brand awareness and wider adoption in the industry."

LexaGene \| 500 Cummings Center, Suite 4550, Beverly, Mass., 01915 \| T 800.215.1824 \| info@lexagene.com

![](tm235853d1_ex99-1img004.jpg)

For more information about LexaGene and the MiQLab System, please visit <u>www.lexagene.com</u> or follow us on <u>Twitter</u> and <u>LinkedIn</u>.

**About LexaGene Holdings Inc.**

LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of biological contaminants, pathogens and other molecular markers. The System is designed for on-site usage and uses real-time PCR chemistry. Our customers include biopharmaceutical companies and veterinary hospitals. The MiQLab System delivers excellent sensitivity, specificity, and breadth of detection.

**Reader Advisory**

*The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.*

*Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to American economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.*

LexaGene \| 500 Cummings Center, Suite 4550, Beverly, Mass., 01915 \| T 800.215.1824 \| info@lexagene.com

![](tm235853d1_ex99-1img003.jpg)

*Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; intellectual property infringement risks, risks relating to any required regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at <u>www.sedar.com</u>. Readers are cautioned that this list of risk factors should not be construed as exhaustive.*

*The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.*

[1] Rapid Micro Biosystems, 2021 10-K SEC filing, filed 03/24/2022

*###*

LexaGene \| 500 Cummings Center, Suite 4550, Beverly, Mass., 01915 \| T 800.215.1824 \| info@lexagene.com